NEWS SHARING
AND CARING: A NOVEL APPROACH TO SMOKING CESSATION All community pharmacists know
how important it is to support patients as they attempt to give up smoking. With that objective in mind, In September, Nicorette will be hosting two meetings to promote a novel approach to ensuring that every quitter gets the support they need to succeed.
Dates and venues are:
6.30pm: Wednesday 21 September 2016, Ramada Da Vinci’s Hotel, Londonderry-Derry City
6.30pm: Thursday 22 September 2016, Malone Lodge Hotel, Eglantine Avenue, Belfast
Registration and food from 6.30pm-7.30pm, then talk starting at 7.30pm.
The speaker will be Dr Alan Curley from UC Mind Solutions, who will present his talk on: ‘Sharing and caring: a novel approach to ensuring every quitter gets the support they need to succeed.’
The meeting is designed to demonstrate how shared care can improve both footfall and quit rates in a pharmacy stop smoking service, and to review the support needs of quitters, especially those from the most disadvantaged backgrounds. The meetings will also provide an update on NRT and how to get the most from these products.
To confirm your attendance at either event, text or email James Griffiths on 07786800757 or
james.griffiths@
apodi.co.uk
4 - PHARMACY IN FOCUS
NEW PHARMACY DEPARTMENT WILL SERVE WHOLE COMMUNITY
the Mid Ulster Hospital site as well as to off-site facilities including Inver Rehabilitation Unit in the Moyle Community Hospital, the Robinson Community Hospital in Ballymoney, the GP Out of Hours Service (Dalriada Urgent Care) and The Rowan. It is ideally located to do this as no trust site is more than an hour away.
(L-r): Health Minister, Michelle O'Neill MLA; Chief Pharmaceutical Officer, Dr Mark Timoney; Professor Mike Scott and Pamela McCready, Director of Operations, Northern Health & Social Care Trust
Health Minister Michelle O’Neill has officially opened the new Pharmacy Department in the Mid Ulster Hospital during a visit to the Northern Trust area.
The Minister opened the new £430,000 refurbished and upgraded former ward, which provides centralised dispensing and distribution
NEW ASTHMA PILL COULD BE ‘GAME CHANGER’
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as ‘a game changer for future treatment of asthma’.
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated
of drugs, dressings, medical and surgical supplies for patients and community services across the Northern Trust.
'I am delighted to open this impressive facility,' the Minister said as she opened the new unit. 'This new department will benefit patients providing one stop dispensing for
in late stage clinical trials for efficacy in patients with severe asthma, according to
ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for twelve weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
People, who do not have asthma, have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to- severe asthma taking the medication was reduced from an average of 5.4 per cent to 1.1 per cent over the course of the twelve weeks, according to the study, which was published recently in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling,
'The new department dispenses and distributes specialist medicines for cancer, multiple sclerosis and renal patients and specialist supplies for diabetic patients who are managed in the community. I am also pleased to hear that the Trust’s pharmacy team has established links on an all-Ireland basis including with Tallaght Hospital in Dublin, University of Limerick and University Hospital Limerick. It is important that we use every opportunity to collaborate so that we reap the benefits of shared learning and all island working.”
who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
‘A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,’ the Professor said.
‘Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
‘We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
‘This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.’
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64